全身性糖皮质激素使用与银屑病关节炎及银屑病急性发作的系统综述
该系统综述检索MEDLINE、EMBASE和Cochrane Library(2019年11月),纳入21篇全文,其中11项回顾性和前瞻性队列共4,171,307例患者。银屑病关节炎患者中6727例(37.82%)、银屑病患者中1,460,793例(35.17%)使用过全身性糖皮质激素;10项观察性/干预性研究未报告与全身性糖皮质激素使用相关的银屑病急性发作风险或发生率增加。
要点
- 银屑病关节炎和银屑病患者中全身性糖皮质激素使用常见(分别37.82%和35.17%)。
- 10项观察性/干预性研究未报告全身性糖皮质激素使用增加银屑病急性发作风险或发生率。
- 作者认为在有明确指征(如需快速抗炎或桥接治疗)时,鉴于皮肤急性发作风险低,应考虑使用全身性糖皮质激素。
核心结论
- 全身性糖皮质激素常用于银屑病关节炎和银屑病患者,暴露后银屑病急性发作似乎较少。
- 作者认为在有明确指征(如需快速抗炎治疗或桥接治疗)的患者中,鉴于皮肤急性发作风险低,应考虑使用全身性糖皮质激素。
- 临床决策中仍需权衡全身性糖皮质激素短期和长期副作用的风险。
研究设计与样本
- 系统综述,检索MEDLINE、EMBASE和Cochrane Library数据库(2019年11月),比较银屑病关节炎和银屑病人群中任何全身性糖皮质激素使用与不使用的研究,排除局部糖皮质激素治疗。
- 共检索到4922篇文章,21篇全文符合纳入标准,其中11项回顾性和前瞻性队列共纳入4,171,307例患者。
主要发现
- 银屑病关节炎患者中6727例(37.82%)和银屑病患者中1,460,793例(35.17%)接受过任何类型的全身性糖皮质激素治疗。
- 10项观察性/干预性研究未报告与全身性糖皮质激素使用相关的银屑病急性发作风险或发生率增加。
临床怎么用
- 作者认为在有明确指征(如需快速抗炎治疗或桥接治疗)的患者中,鉴于皮肤急性发作风险低,应考虑使用全身性糖皮质激素。
- 作者指出临床决策中仍需权衡全身性糖皮质激素短期和长期副作用的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The use of systemic glucocorticoids (SGCs) is traditionally discouraged in the treatment of PsA and psoriasis due to the risk of psoriatic flares. However, despite this recommendation, SGCs are frequently prescribed for these patients. In this study we reappraise the old paradigm that SGCs are contra-indicated in the treatment of PsA and psoriasis. METHODS: A systematic search of MEDLINE, EMBASE and the Cochrane Library databases was performed in November 2019 to identify articles on any SGC use compared with no use in the PsA and psoriasis population. Topical glucocorticoid treatment was excluded. Our two primary outcomes focused on the prescribing characteristics and the occurrence of any type of flare. RESULTS: Our search yielded 4922 articles, and of these 21 full-text articles were eligible for inclusion. There were 11 retro- and prospective cohorts involving a total of 4,171,307 patients. Of these, 6727 (37.82%) of the patients with PsA and 1 460 793 (35.17%) of the patients with psoriasis were treated with any type of SGC. Ten observational/interventional studies did not report an increased risk or occurrence of psoriatic flares related to SGC use. CONCLUSION: Our results indicate that SGCs are frequently prescribed for PsA and psoriasis patients. The occurrence of psoriatic flares appears to be low upon SGC exposure. In patients with a clear indication for SGCs, e.g. in need of rapid anti-inflammatory therapy or bridging of therapies, the use of SGCs should be considered in view of the low risk of skin flaring. It remains of importance to weigh risks for short- and long-term SGC-related side effects in clinical decision making.
引用
- Vincken NLA, Balak DMW, Knulst AC, et al. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Rheumatology (Oxford). 2022. PMID: 35285486. doi:10.1093/rheumatology/keac129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。